{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-056585","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.241674+00:00","generated_at":"2026-06-28T12:44:47.299991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Protara Therapeutics reports Q3 2021 net loss of $10.8M; FDA clears IND for TARA-002 in NMIBC","bullets":["Net loss $10.8M ($0.96/sh) vs $8.0M ($1.26/sh) in Q3 2020; R&D expense $4.1M (up from $2.8M), G&A $6.7M (up from $5.3M).","Cash, equivalents and marketable debt securities $138.4M as of Sept 30, 2021.","FDA cleared IND for TARA-002 in non-muscle invasive bladder cancer; Phase 1 trial start planned by year-end 2021.","Hired Mary Grendell (ex-Intercept Pharmaceuticals) as General Counsel; completed GMP comparability for TARA-002."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-056585","json":"https://secwatch.observer/filing/0001213900-21-056585.json","markdown":"https://secwatch.observer/filing/0001213900-21-056585.md","text":"https://secwatch.observer/filing/0001213900-21-056585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390021056585/0001213900-21-056585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390021056585/ea149909-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:44:47.299991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}